Traduction de «which is expected to form » (Néerlandais → Français) :

QAB149, which is expected to form the cornerstone of planned combination therapies in development against COPD, was submitted for US and European regulatory review in late 2008.
QAB149, qui pourrait devenir la pierre angulaire des traitements en développement contre la BPCO, a été soumis aux fins d’examen par les autorités réglementaires aux Etats-Unis et en Europe.

The first trial in the US, which was expected to begin in Virginia in June 2010, has therefore been postponed.
Par conséquent, le premier procès aux Etats-Unis, qui devait débuter en juin 2010 en Virginie, a été repoussé.

The transaction, which is expected to be completed in 2010, is subject to certain closing conditions, including receipt of government and regulatory approvals in China.
Cette transaction, qui devrait être terminée en 2010, est soumise à certaines conditions, notamment son acceptation par le gouvernement et l’approbation des autorités réglementaires de Chine.

The transaction, which is expected to be completed in 2010 or early 2011, is subject to certain closing conditions, including receipt of government and regulatory approvals in China.
Cette transaction, qui devrait être terminée en 2010 ou début 2011, est soumise à certaines conditions, notamment son acceptation par le gouvernement et l’approbation des autorités réglementaires de Chine.

In anticipation of changes to the product portfolio in the US, which includes expected approvals for a number of new specialty medicines but also the loss of market exclusivity for Diovan and other medicines in the next few years, Novartis has further streamlined its US business in Pharmaceuticals to maximize the potential of the changing portfolio in both primary care and specialty markets.
Novartis anticipe les changements qui vont intervenir au cours des années à venir dans son portefeuille de produits aux Etats-Unis, notamment les autorisations attendues pour de nouvelles spécialités mais aussi la perte de l’exclusivité du marché pour Diovan et d’autres médicaments. C’est ainsi que Pharmaceuticals a encore rationalisé ses opérations américaines pour maximiser le potentiel d’un portefeuille en plein changement, à la fois dans les soins de santé primaires et dans les marchés des spécialités.

At the start of 2008 forms and user guides were sent to managers of cell and tissue banks in order to encourage voluntary reporting in expectation of the national transposition of the relevant European directive which made
At the start of 2008 forms and user guides were sent to managers of cell and tissue banks in order to encourage voluntary reporting in expectation of the national transposition of the relevant European directive which made

1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines
1974 on the opening, transfer and merger of retail pharmacies Royal decree of 9 July 1984 on the provision of information and advertising relating to medicines Royal decree of 11 January 1993 determining the conditions under which medicines for human use may be supplied in sample form Royal decree of 7 April 1995 on the provision of information and advertising relating to medicines for human use Royal decree of 15 July 1997 on active implantable medical devices, transposing Directive 90/385 EEC (AIMD) Royal decree of 19 December 1997 on the control and analysis of the raw materials used by dispensing chemists Royal decree of 18 March 1999 on medical devices, transposing Directive 93/42/EEC of 14 June 1993 (MDD) Royal decree of 11 July 2003 determining the conditions under which medicines for veterinary use may be supplied in sample form Law of 16 December 2004 modifying the regulations on combating abuses in the promotion of medicines Royal decree of 10 June 2006 establishing the report point referred to in Article 10, § 5, of the law of 25 March 1964 on medicines Royal decree of 23 November 2006 implementing Article 10, § 3, of the law of 25 March 1964 on medicines Royal decree of 25 February 2007 recognising the institutions referred to in Article 10 § 3 of the law of 25 March 1964 on medicines

The purchase of the 52% stake, which is subject to required regulatory approvals, is expected to be completed in the second half of 2010.
L’achat de la part de 52% devrait être finalisé au second semestre 2010, sous réserve de l’approbation des autorités réglementaires.

It is crucial to take advantage of the moment of crisis and the moment at which the suicidal act is being carried out to make extensive use of the issues of the patient as well as those of the whole system of which he/she forms a part.
Il est capital de profiter du moment de crise et de passage à l’acte suicidaire pour mobiliser de manière intensive la problématique du patient mais aussi de tout le système dans lequel il s’intègre.

This expectation includes sales of A(H1N1) pandemic flu vaccines, which, year over year, is broadly neutral to overall sales growth.
Cette prévision comprend les ventes des vaccins A(H1N1) contre la pandémie de grippe comprises dans les deux années et ayant un impact neutre sur la hausse globale du chiffre d’affaires.